Wave Life Sciences Ltd. Stock News

Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Joon Lee - Truist Securities, ...

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)

Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Erik Ingelsson - Chief Scientific Officer Kate Rausch - Head of Investor Relations Kyle B.

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company's second quarter 2025 financial results and provide business updates.

Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying opportunity for a risk-on investor. Wave is partnered with GSK over its AATD program which recently demonstrated proof-of-concept and opens up the possibility of triple-digit million milestone payments.

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation